Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
← catalyst calendarNCT05581303 · readout in 590 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
7,297actual
Sites
737
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-14 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atherosclerotic Cardiovascular Disease
Interventions
- Drug: Placebo
- Drug: Olpasiran
Primary outcome
what the primary-completion date above is the date OFTime to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first
measured Approximately 5 years
Publications
- PMID 41841810 — linked by the registry
- PMID 41329869 — linked by the registry
- PMID 39329200 — linked by the registry
- PMID 39322524 — linked by the registry
- PMID 38682459 — linked by the registry
- PMID 38415744 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed